Articles from Amwell

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL), a leader in digital care, will report fourth quarter 2024 operating results after stock market trading hours on Wednesday, Feb. 12.

Vida to offer cardiometabolic solutions including GLP-1s and other anti-obesity medications on the Amwell platform

Divestment of Amwell Psychiatric Care intended to focus product portfolio on key growth initiatives

Seasoned leader assumes responsibility for operations and sales as COO

BOSTON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL), a leader in digital care, today announced that, on November 4, 2024, it made a grant of restricted stock units (“RSUs”) covering 254,227 shares of its Class A common stock to Mark Hirschhorn. The grant was offered as material inducement to Mr. Hirschhorn’s employment as Amwell’s chief financial officer. The RSUs become vested as follows, subject to Mr. Hirschhorn’s continued employment through each vesting date, except as noted below: 25% of the RSUs vested on the grant date, and the remaining 75% of the RSUs will vest in substantially equal quarterly installments over a three-year period, starting on the one-year anniversary of the grant date, with the first vesting date for the remaining 75% portion occurring on the first day of the first month following the 15-month anniversary of the grant date and with subsequent vesting dates occurring on each three-month anniversary thereof until such RSUs are fully vested on the four-year anniversary of the grant date. In addition, Mr. Hirschhorn is eligible for an additional grant with a total value of up to $5,000,000. The additional grant will vest in substantially equal annual installments on each of the first four anniversaries of Mr. Hirschhorn’s employment start date, provided that Mr. Hirschhorn remains employed by the company through the applicable vesting date and applicable EBITDA targets and appreciation of company valuation targets, in each case, as determined by Amwell’s board of directors or the compensation committee of the board of directors in its sole discretion, are achieved. The additional grant, to the extent it becomes vested, will be settled in cash, unless and to the extent the board of directors or the compensation committee of the board of directors determines in its sole discretion that it will be settled in shares of Class A common stock or other property. As set forth in Mr. Hirschhorn’s employment agreement, if Mr. Hirschhorn’s employment is terminated by the company without cause or by Mr. Hirschhorn with good reason, conditioned on Mr. Hirschhorn’s execution and non-revocation of a release of claims, the aforementioned grants will vest as to the portion that would have vested had Mr. Hirschhorn remained employed by the company through the first anniversary of his termination date. In addition, if the involuntary termination of employment occurs one month before or within 24 months following a change in control, the aforementioned grants will fully vest at the time of termination.

BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the third quarter ended Sept. 30, 2024. Visit Amwell’s investor relations website at investors.amwell.com to view the third quarter 2024 earnings report.

BOSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL), a leader in digital care, announced company leaders will participate in several upcoming investor conferences. Ido Schoenberg, M.D., Amwell chairman and chief executive officer, and Mark Hirschhorn, Amwell chief financial officer, will participate in fireside chats or one-on-one meetings at these events:

Industry veteran Mark Hirschhorn joins Amwell leadership team

BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL), a leader in digital care, will report third quarter 2024 operating results on Wednesday, Oct. 30.

Hello Heart selects Amwell platform to extend its reach across patient populations

Boston, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL), a leader in hybrid care enablement, announced that the company will participate in several investor conferences in September.

Boston, July 31, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the second quarter ended June 30, 2024. Visit Amwell’s investor relations website at investors.amwell.com to view the second quarter 2024 earnings report.

Boston, July 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL), a leader in hybrid care enablement, will report its second quarter 2024 operating results on Wednesday, July 31.

Boston, June 28, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL), a small-cap growth healthcare company and a leading provider of healthcare software as a service, today announced that its Board of Directors (the “Board”) has approved a 1-for-20 reverse stock split (“Reverse Split”) of its Class A common stock, Class B common stock and Class C common stock (collectively, the “Common Stock”), that is expected to become effective on July 10, 2024 at 5:00 p.m. EDT. The shares of the Company’s Class A common stock are expected to begin trading on the New York Stock Exchange (“NYSE”) on a split-adjusted basis at the market open on July 11, 2024. No change will be made to the trading symbol for the Company’s shares of Class A common stock, “AMWL”, in connection with the Reverse Split. 

Boston, June 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL), a leader in hybrid care enablement, today announces the appointment of Ricky Goldwasser to the company's Board of Directors, effective June 13.

Amwell CEO to join tech and health leaders from Apple, Stanford Health and others in discussing virtual care solutions that bolster accessibility

Amwell CEO to join tech and health leaders from Apple, Stanford Health and others in discussing virtual care solutions that bolster accessibility

Boston, May 01, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the first quarter ended March 31, 2024. Visit Amwell’s investor relations website at investors.amwell.com to view the first quarter 2024 earnings report.

Report demonstrates company progress toward enabling digital healthcare with purpose

Boston, April 25, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL), a leader in hybrid care enablement, announced that the company will participate in the Needham Technology, Media and Consumer Conference. 

Boston, April 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL), a leader in hybrid care enablement, will report its first quarter 2024 operating results Wednesday, May 1.

Amwell’s Class A Common Stock continues to trade on the NYSE

Amwell clients to present on automated care, Converge platform integration

Horner brings to the role 25 years in family medicine, completion of 25,000 virtual care visits

Amplar Health to leverage Amwell’s digital care technology for chronic disease prevention programs

Boston, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL), a leader in hybrid care enablement, announced that company executives will participate in the TD Cowen Health Care Conference on Tuesday, March 5 in Boston. 

Company leaders to moderate or speak at sessions on virtual care delivery, GLP-1s

Boston, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL) a leader in hybrid care enablement, today announced financial results for the fourth quarter and full year ended Dec. 31, 2023. Amwell is a small-cap growth company and a leading provider of healthcare software as a service. 

Boston, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSEAMWL), a leader in digital healthcare enablement, will report its fourth quarter 2023 operating results on Wednesday, Feb. 14. 

Amwell® (NYSEAMWL), a leader in hybrid care enablement, today announced financial results for the third quarter ended Sept. 30, 2023.

Amwell®, (NYSEAMWL) a leader in digital healthcare enablement, today announced participation in the following investor conferences and events:

Amwell® (NYSEAMWL), a leader in hybrid healthcare enablement, together with Leidos NYSE: LDOSNYSELDOS)

Amwell® (NYSEAMWL), a leader in hybrid health care enablement, today announced it will report its third-quarter 2023 operating results on Wednesday, November 1, 2023. Following distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. Eastern time to review the company's operating results and provide a general business update.

Amwell® (NYSEAMWL), a leader in hybrid health care enablement, today announced a collaboration with Nestlé Health Science, a global leader in the science of nutrition, to help health organizations improve patients’ overall health through innovative digital solutions focused on nutrition. Together the companies are developing a portfolio of novel solutions to help improve clinical and financial outcomes.

Amwell® (NYSEAMWL), a global leader in hybrid care enablement, is attending the HLTH 2023 conference, Oct. 8-10, in Las Vegas. During the conference, Amwell executives will meet with interested parties to discuss the future of digital health, the evolution of virtual primary care and newly announced strategic partnerships that strengthen the organization’s ability to advance hybrid care, benefiting patients, providers, and the healthcare system.

Amwell (NYSEAMWL):

Health Gorilla, a privacy-focused health information network and interoperability solution provider, and Amwell® (NYSEAMWL), a global leader in hybrid care enablement, announce a new lab capability within the Amwell Converge™ virtual care platform. Providers practicing on the Converge platform will be able to offer patients a more connected hybrid care experience through streamlined lab processes, enhanced digital diagnostic data capabilities, and access to a broader nationwide lab network.

Amwell® (NYSEAMWL), a leader in digital healthcare enablement, today announced three of its partner health systems will lead a panel discussion during the 2023 Oracle Health Conference.

OSF HealthCare, an integrated health system with more than 150 locations in Illinois and Michigan, has achieved significant clinical outcome improvements across its behavioral health patient community by leveraging the Amwell Converge™ platform. Results include:

Amwell®, (NYSEAMWL) a leader in digital healthcare enablement, today announced participation in the following investor conferences:

Amwell® (NYSEAMWL), a leader in hybrid care enablement, today announced financial results for the second quarter ended June 30, 2023.

Amwell® (NYSEAMWL), a leader in hybrid health care enablement, today announced it will report its second quarter 2023 operating results on Wed., Aug. 2, 2023. Following distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. Eastern Time to review the company's operating results and provide a general business update.

Amwell® (NYSEAMWL), a leader in hybrid care enablement, released results of a survey that asked employed U.S. adults about their experience seeking behavioral health treatment and how these factors relate to their health plan and employer offerings. Key findings from the survey include:

Amwell® (NYSEAMWL), a leader in digital healthcare enablement, today announced the appointment of Kathy Weiler as Executive Vice President, Chief Commercial and Growth Officer, effective June 1, 2023. As a member of Amwell’s executive leadership team, Weiler will lead the company’s growth strategy, driving strategic initiatives and leading the business development, sales and account management, commercial enablement, marketing, and strategic and channel partnerships teams. Weiler will partner with Amwell clients to help them achieve greater clinical, operational and financial outcomes by leveraging the Amwell Converge™ platform to deliver digitally enabled hybrid care solutions at scale.

Amwell® (NYSEAMWL), a leader in digital healthcare enablement, today announced financial results for the first quarter ended March 31, 2023.

Amwell®, (NYSEAMWL) a leader in digital healthcare enablement, today announced participation in the following investor conferences:

Amwell® (NYSEAMWL), a leader in digital health care enablement, today announced it will report its first-quarter 2023 operating results on Wed., May 3, 2023. Following distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. Eastern time to review the company's operating results and provide a general business update.

Amwell® (NYSEAMWL), a leader in digital healthcare enablement, today announced the expansion of its digital clinical programs to include a cardiometabolic program, enabling health plans and clinicians to seamlessly connect members living with common chronic diseases, such as diabetes and high blood pressure, to Dario’s highly personalized digital therapeutic solution on the Amwell platform.

Amwell® (NYSEAMWL), a leader in digital healthcare enablement, today announced financial results for the fourth quarter and full year ended December 31, 2022.

Amwell®, (NYSEAMWL) a leader in digital healthcare enablement, today announced that its CFO, Robert Shepardson, will participate in a fireside chat at the Cowen 43rd Annual Healthcare Conference on March 7, 2023 at 9:10AM ET.

Amwell®, (NYSEAMWL) a leader in digital healthcare enablement, today announced that it will report fourth quarter, ended December 31, 2022, operating results on Wednesday, February 22, 2023. Following distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5:00 p.m. Eastern Time to review the Company's operating results and provide a general business update.

Amwell® (NYSEAMWL), a leader in digital healthcare enablement, today announced financial results for the third quarter ended September 30, 2022.

Amwell®, (NYSEAMWL) a leader in digital healthcare enablement, today announced the appointment of Robert Webb to the Company’s Board of Directors, effective immediately. Mr. Webb will further strengthen the Amwell Board and market position, bringing deep healthcare technology leadership experience, stemming from his more than 30 years as a growth executive, operator, and investor.

Amwell®, (NYSEAMWL) a leader in digital healthcare enablement, today announced that members of the Amwell management team will participate in the following upcoming investor conferences:

Amwell®, (NYSEAMWL) a leader in digital healthcare enablement, today announced that it will report third quarter ended September 30, 2022 operating results on Monday November 7, 2022. Following distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5:00 p.m. Eastern Time to review the Company's operating results and provide a general business update.

Amwell® (NYSEAMWL), a digital care delivery leader, today announced the appointments of Vaughn Paunovich to the role of Executive Vice President, Enterprise Platforms, and Matthew McAllister to Chief Product Officer. Vaughn will oversee technological delivery and innovation, including for Converge™, Amwell’s enterprise grade digital care delivery platform, and Matthew will join Vaughn’s leadership team with responsibility for product management and design.

Amwell®, (NYSEAMWL) a digital care delivery leader, today announced the release of its inaugural Environmental, Social and Governance (“ESG”) Framework. The Framework provides insight into the Company’s business, across three key areas: people, products, and operations, as viewed through an ESG lens.

Amwell®, (NYSEAMWL) a digital care delivery leader, today announced that members of the Amwell management team will participate in the following upcoming investor conferences:

Amwell® (NYSEAMWL), a digital care delivery leader, today announced financial results for the second quarter ended June 30, 2022.

Amwell®, (NYSEAMWL) a digital care delivery leader, today announced that it will report second quarter ended June 30, 2022 operating results on Thursday August 4, 2022. Following distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5:00 p.m. Eastern Time to review the Company's operating results and provide a general business update.

Amwell® (NYSEAMWL), a digital care delivery leader, has named Dr. Carrie Nelson as its new Chief Medical Officer. In this role, Dr. Nelson will focus on empowering provider and payer organizations as they seek to achieve greater clinical, operational, and financial outcomes through digital care delivery powered by Converge™, Amwell’s enterprise-grade infrastructure software platform. Dr. Nelson will also be responsible for leading clients in their improvement of population health in today’s new era of hybrid healthcare and will have clinical oversight of healthcare professionals practicing on behalf of Amwell clinical partner, the Amwell Medical Group.

Amwell® (NYSEAMWL), a digital care delivery leader, today announced the continued expansion of its ecosystem with the launch of the Amwell Comprehensive Behavioral Health Program, an evidence-based, comprehensive and scalable behavioral health solution that can be tailored to meet specific population needs across the full spectrum of care. Designed to address the growing mental health crisis, the Amwell program enables payers and providers to deliver integrated solutions including virtual therapy and psychiatry, coaching, and digital mental health programs with personalized experiences to address various severities and preferences of care delivery.

Amwell® (NYSEAMWL), a digital care delivery leader, today announced it has reached an agreement to shorten the earnout period associated with its acquisition of SilverCloud Health, the digital mental health company it purchased in August, 2021. As a result of this renegotiation, Amwell issued an aggregate of 4,959,856 shares of the Company’s Class A common stock to the former stockholders of SilverCloud Health. The news comes on the heels of Amwell announcing the early termination of the earnout associated with its acquisition of Conversa Health.

Amwell® (NYSEAMWL), a national telehealth leader, today announced financial results for the first quarter ended March 31, 2022.

Amwell® (NYSEAMWL), a national telehealth leader, today announced Susan Worthy has joined the company as Chief Marketing Officer. Susan is a tenured marketing executive with more than 25 years of experience leading marketing for healthcare services and technology companies. In her new role, Susan will be responsible for leading Amwell’s overall marketing strategy and will play a pivotal part in building upon the company’s market position to drive continued growth, as well as shareholder and customer value.

Amwell®, (NYSEAMWL) a national telehealth leader, today announced that members of the Amwell management team will participate in the following upcoming investor conferences:

Amwell® (NYSEAMWL), a national telehealth leader, today announced the expansion of its virtual specialty provider and clinical program portfolio by adding Amwell Musculoskeletal (MSK) and Dermatology programs. These new programs are designed to address some of the most pervasive and costly areas of healthcare and are part of Amwell efforts to enable health plans to better care for members across a wide breadth of specialty care areas and provide a holistic member experience. As with the entire Amwell platform, health plans can brand and use any or all of these programs as part of their own digital offerings.

Amwell®, (NYSEAMWL) a national telehealth leader, today announced that it will report first quarter ended March 31, 2022 operating results on Monday, May 9, 2022. Following distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5:00 p.m. Eastern Time to review the Company's operating results and provide a general business update.

Amwell® (NYSEAMWL), a leading enterprise software company enabling digital delivery of care for healthcare’s key stakeholders, today announced that it has reached an agreement to shorten the earnout period associated with its acquisition of Conversa Health, the automated care company it purchased in August, 2021. This change further allows Amwell to accelerate the integration and alignment of Conversa in support of new product development, cross-selling opportunities, and operational efficiencies. As a result of this renegotiation, Amwell issued an aggregate of 1,020,964 shares of the Company’s Class A common stock to the former stockholders of Conversa Health.

Amwell® (NYSEAMWL) (the "Company"), a leading enterprise software company enabling digital delivery of care for healthcare’s key stakeholders, today announced financial results for the fourth quarter and full year ended December 31, 2021.

Amwell®, (NYSEAMWL) (the "Company") a national telehealth leader, today announced that it will report fourth quarter and full year ended December 31, 2021 operating results on Thursday, February 24, 2022. Following distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5:00 p.m. Eastern Time to review the Company's operating results and provide a general business update.

Amwell® (NYSEAMWL), a national telehealth leader, today announced the launch of “Mind Your Mind” a new mental health initiative designed to raise awareness for mental health issues and help people receive care via a licensed therapist or psychologist through the award-winning Amwell mobile app or desktop experience, at a low cost. As part of this initiative, Amwell is partnering with actress, singer, and mental health advocate Ashley Tisdale and additional social influencers to offer a limited-time promotion ($10 first visit) to people who use the exclusive coupon codes including ASHLEY10 from Dec. 2021 through Feb. 2022.

Amwell® (NYSEAMWL) (the "Company"), a national telehealth leader, today announced financial results for the third quarter ended September 30, 2021.

Amwell®, (NYSEAMWL) (the "Company") a national telehealth leader, today announced that it will report third quarter ended September 30, 2021, operating results on Wednesday, November 10, 2021. Following distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast at 5:00 p.m. Eastern Time to review the Company's operating results and provide a general business update.

Amwell® (NYSEAMWL), a national telehealth leader, today announced the general availability of Converge™ for EHRs, adding built in EHR integration capabilities to the Converge platform, alongside the standalone Amwell Now on Converge, which has been deployed in over 40 health systems. Converge is designed to offer a scalable, simple and unified digital care delivery experience across the care continuum. The announcement comes as Amwell’s Converge Platform is named Best New Application in Telehealth by UCSF, a Tech Top 50 by the Massachusetts Technology Leadership Council (MassTLC), and is called out as a driver behind Amwell being named Chilmark Research’s Flagship Vendor in Omnichannel Functionality.